Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials
Copyright © 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Clinical trials provide conflicting evidence regarding oral factor Xa inhibitors for prevention of ischemic stroke in patients without a history of atrial fibrillation (AF).
METHODS: We performed a critical appraisal of randomized clinical trials that tested oral factor Xa inhibitors in patients without AF that reported ischemic stroke.
RESULTS: Considering the 11 trials that reported > 10 ischemic strokes during follow-up (97,578 participants, 1195 ischemic strokes), 1 tested apixaban (57 strokes), 1 betrixaban (52 strokes), and 9 rivaroxaban (1086 strokes). In 7 trials with placebo comparisons, numerically fewer ischemic strokes occurred among those assigned factor Xa inhibitors in 7 of 8 randomized comparisons (range of hazard ratios [HRs], 0.89-0.51), including statistically significant reductions in 2 trials that compared rivaroxaban 2.5 mg twice daily vs placebo on a background of aspirin in patients with cardiovascular disease, COMPASS (HR, 0.51; 95% confidence interval [CI], 0.38-0.68) and COMMANDER-HF (HR, 0.64; 95% CI, 0.43-0.95). Compared with aspirin in 4 trials, oral factor Xa inhibitors were associated with fewer ischemic strokes in 2, with statistically significant reduction in 1 (rivaroxaban 5 mg twice daily in COMPASS; HR, 0.69; 95% CI, 0.53-0.90). Major bleeding was increased by oral factor Xa inhibitors in all 7 placebo-controlled trials (HR range, 1.42-4.08), with statistically significant increases reported in 5 trials, and in all 4 aspirin-controlled trials (all statistically significant increases; HR range, 1.52-2.72).
CONCLUSIONS: Aggregate evidence on the basis of placebo comparisons from randomized trials supports the potential for oral factor Xa inhibitors to reduce ischemic stroke in patients without AF, but major bleeding is increased.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
---|---|
Enthalten in: |
The Canadian journal of cardiology - 39(2023), 2 vom: 30. Feb., Seite 187-197 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hart, Robert G [VerfasserIn] |
---|
Links: |
---|
Themen: |
9NDF7JZ4M3 |
---|
Anmerkungen: |
Date Completed 07.02.2023 Date Revised 09.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.cjca.2022.09.022 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM346954630 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM346954630 | ||
003 | DE-627 | ||
005 | 20231226032701.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cjca.2022.09.022 |2 doi | |
028 | 5 | 2 | |a pubmed24n1156.xml |
035 | |a (DE-627)NLM346954630 | ||
035 | |a (NLM)36179950 | ||
035 | |a (PII)S0828-282X(22)00895-9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hart, Robert G |e verfasserin |4 aut | |
245 | 1 | 0 | |a Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2023 | ||
500 | |a Date Revised 09.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Clinical trials provide conflicting evidence regarding oral factor Xa inhibitors for prevention of ischemic stroke in patients without a history of atrial fibrillation (AF) | ||
520 | |a METHODS: We performed a critical appraisal of randomized clinical trials that tested oral factor Xa inhibitors in patients without AF that reported ischemic stroke | ||
520 | |a RESULTS: Considering the 11 trials that reported > 10 ischemic strokes during follow-up (97,578 participants, 1195 ischemic strokes), 1 tested apixaban (57 strokes), 1 betrixaban (52 strokes), and 9 rivaroxaban (1086 strokes). In 7 trials with placebo comparisons, numerically fewer ischemic strokes occurred among those assigned factor Xa inhibitors in 7 of 8 randomized comparisons (range of hazard ratios [HRs], 0.89-0.51), including statistically significant reductions in 2 trials that compared rivaroxaban 2.5 mg twice daily vs placebo on a background of aspirin in patients with cardiovascular disease, COMPASS (HR, 0.51; 95% confidence interval [CI], 0.38-0.68) and COMMANDER-HF (HR, 0.64; 95% CI, 0.43-0.95). Compared with aspirin in 4 trials, oral factor Xa inhibitors were associated with fewer ischemic strokes in 2, with statistically significant reduction in 1 (rivaroxaban 5 mg twice daily in COMPASS; HR, 0.69; 95% CI, 0.53-0.90). Major bleeding was increased by oral factor Xa inhibitors in all 7 placebo-controlled trials (HR range, 1.42-4.08), with statistically significant increases reported in 5 trials, and in all 4 aspirin-controlled trials (all statistically significant increases; HR range, 1.52-2.72) | ||
520 | |a CONCLUSIONS: Aggregate evidence on the basis of placebo comparisons from randomized trials supports the potential for oral factor Xa inhibitors to reduce ischemic stroke in patients without AF, but major bleeding is increased | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
650 | 7 | |a Rivaroxaban |2 NLM | |
650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
650 | 7 | |a Aspirin |2 NLM | |
650 | 7 | |a R16CO5Y76E |2 NLM | |
650 | 7 | |a Anticoagulants |2 NLM | |
700 | 1 | |a Katsanos, Aristeidis H |e verfasserin |4 aut | |
700 | 1 | |a Perera, Kanjana S |e verfasserin |4 aut | |
700 | 1 | |a Eikelboom, John W |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Canadian journal of cardiology |d 1993 |g 39(2023), 2 vom: 30. Feb., Seite 187-197 |w (DE-627)NLM012635553 |x 1916-7075 |7 nnns |
773 | 1 | 8 | |g volume:39 |g year:2023 |g number:2 |g day:30 |g month:02 |g pages:187-197 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cjca.2022.09.022 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 39 |j 2023 |e 2 |b 30 |c 02 |h 187-197 |